Literature DB >> 24092447

Intensity of follow-up after pancreatic cancer resection.

Jason A Castellanos1, Nipun B Merchant.   

Abstract

The prognosis of patients diagnosed with pancreatic adenocarcinoma remains dismal. Of the 15-20 % of patients who are candidates for potentially curative resection, 66-92 % will develop recurrent disease. Although guidelines for surveillance in the postoperative setting exist, they are not evidence based, and there is wide variability of strategies utilized. Current surveillance guidelines as suggested by the National Comprehensive Cancer Network (NCCN) include routine history and physical, measurement of serum cancer-associated antigen 19-9 (CA19-9) levels, and computed tomographic imaging at 3- to 6-month intervals for the first 2 years, and annually thereafter. However, the lack of prospective clinical data examining the efficacy of different surveillance strategies has led to a variability of the intensity of follow-up and a lack of consensus on its necessity and efficacy. Recent therapeutic advances may have the potential to significantly alter survival after recurrence, but a careful consideration of current surveillance strategies should be undertaken to optimize existing approaches in the face of high recurrence and low survival rates.

Entities:  

Mesh:

Year:  2013        PMID: 24092447      PMCID: PMC4066734          DOI: 10.1245/s10434-013-3289-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  43 in total

1.  One thousand consecutive pancreaticoduodenectomies.

Authors:  John L Cameron; Taylor S Riall; JoAnn Coleman; Kenneth A Belcher
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

2.  A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer.

Authors:  Thomas J Howard; Joseph E Krug; Jian Yu; Nick J Zyromski; C Max Schmidt; Lewis E Jacobson; James A Madura; Eric A Wiebke; Keith D Lillemoe
Journal:  J Gastrointest Surg       Date:  2006-12       Impact factor: 3.452

3.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

4.  The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.

Authors:  Umashankar K Ballehaninna; Ronald S Chamberlain
Journal:  J Gastrointest Oncol       Date:  2012-06

5.  Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan.

Authors:  Chi-Yang Chang; Shih-Pei Huang; Han-Mo Chiu; Yi-Chia Lee; Min-Fong Chen; Jaw-Town Lin
Journal:  Hepatogastroenterology       Date:  2006 Jan-Feb

6.  Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer.

Authors:  Ralf Wilkowski; Martin Thoma; Christiane Bruns; Eckhard Dühmke; Volker Heinemann
Journal:  JOP       Date:  2006-01-11

Review 7.  Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer.

Authors:  K S Goonetilleke; A K Siriwardena
Journal:  Eur J Surg Oncol       Date:  2006-11-09       Impact factor: 4.424

8.  Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population.

Authors:  Jee-Eun Kim; Kyu Taek Lee; Jong Kyun Lee; Seung Woon Paik; Jong Chul Rhee; Kyoo Wan Choi
Journal:  J Gastroenterol Hepatol       Date:  2004-02       Impact factor: 4.029

9.  Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas.

Authors:  R C Montgomery; J P Hoffman; L B Riley; A Rogatko; J A Ridge; B L Eisenberg
Journal:  Ann Surg Oncol       Date:  1997 Oct-Nov       Impact factor: 5.344

10.  Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection.

Authors:  Daniel Habermehl; Ingo C Brecht; Frank Bergmann; Thomas Welzel; Stefan Rieken; Jens Werner; Peter Schirmacher; Markus W Büchler; Jürgen Debus; Stephanie E Combs
Journal:  Radiat Oncol       Date:  2013-01-31       Impact factor: 3.481

View more
  10 in total

1.  Primary Recurrence in the Lung is Related to Favorable Prognosis in Patients with Pancreatic Cancer and Postoperative Recurrence.

Authors:  Biao Zheng; Kenoki Ohuchida; Zilong Yan; Takashi Okumura; Takao Ohtsuka; Masafumi Nakamura
Journal:  World J Surg       Date:  2017-11       Impact factor: 3.352

2.  Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer.

Authors:  Walid L Shaib; Amit Surya Narayan; Jeffrey M Switchenko; Sujata R Kane; Christina Wu; Mehmet Akce; Olatunji B Alese; Pretesh R Patel; Shishir K Maithel; Juan M Sarmiento; David A Kooby; Bassel F El-Rayes
Journal:  Cancer       Date:  2018-11-20       Impact factor: 6.860

3.  Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer.

Authors:  Walid L Shaib; Katerina Zakka; Asser A Shahin; Fares Yared; Jeffrey M Switchenko; Christina Wu; Mehmet Akce; Olatunji B Alese; Pretesh R Patel; Mark Mcdonald; Bassel F El-Rayes
Journal:  Pancreas       Date:  2020-07       Impact factor: 3.327

4.  Impact of surveillance among patients with resected pancreatic cancer following adjuvant chemotherapy.

Authors:  Selina K Wong; Lovedeep Gondara; Daniel J Renouf; Howard J Lim; Jonathan M Loree; Janine M Davies; Sharlene Gill
Journal:  J Gastrointest Oncol       Date:  2021-04

5.  Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma.

Authors:  Tao Chen; Min-Gui Zhang; Hua-Xiang Xu; Wen-Quan Wang; Liang Liu; Xian-Jun Yu
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

6.  SEOM Clinical Guideline for the treatment of pancreatic cancer (2016).

Authors:  R Vera; E Dotor; J Feliu; E González; B Laquente; T Macarulla; E Martínez; J Maurel; M Salgado; J L Manzano
Journal:  Clin Transl Oncol       Date:  2016-11-28       Impact factor: 3.405

7.  Oncologic outcomes according to the location and status of resection margin in pancreas head cancer: role of radiation therapy in R1 resection.

Authors:  Hee Ju Sohn; Hongbeom Kim; Sun Joo Kim; Kyung Bun Lee; Youngmin Han; Jung Min Lee; Jae Seung Kang; Wooil Kwon; Eui Kyu Chie; Haeryoung Kim; Jin-Young Jang
Journal:  Ann Surg Treat Res       Date:  2022-01-03       Impact factor: 1.859

8.  Meta-analyses of treatment standards for pancreatic cancer.

Authors:  Jun Gong; Richard Tuli; Arvind Shinde; Andrew E Hendifar
Journal:  Mol Clin Oncol       Date:  2015-12-18

9.  The microRNA expression signature of pancreatic ductal adenocarcinoma by RNA sequencing: anti-tumour functions of the microRNA-216 cluster.

Authors:  Keiichi Yonemori; Naohiko Seki; Tetsuya Idichi; Hiroshi Kurahara; Yusaku Osako; Keiichi Koshizuka; Takayuki Arai; Atsushi Okato; Yoshiaki Kita; Takaaki Arigami; Yuko Mataki; Yuko Kijima; Kosei Maemura; Shoji Natsugoe
Journal:  Oncotarget       Date:  2017-07-26

10.  Value of regular endosonography and [18F]fluorodeoxyglucose PET-CT after surgery for gastro-oesophageal junction, stomach or pancreatic cancer.

Authors:  O S Bjerring; S Hess; H Petersen; C W Fristrup; L Lundell; M B Mortensen
Journal:  BJS Open       Date:  2021-03-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.